In this review, we focus on small-molecule inhibitors of HSPs, with particular emphasis on HSP90 [Figure 2] and HSP70 [Figure 3], which represent the most extensively studied and therapeutically relevant subtypes in cancer drug resistance. The gene discussed is HSP90AB1; the disease is cancer.